Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation

Inclusion Criteria: * Male or female aged 18-64 years (both inclusive) at the time of signing informed consent * Subjects diagnosed with type 2 diabetes (diagnosed regarding world health organization \[WHO\] criteria) and on stable treatment for a period of 90 days prior to screening with metformin as monotherapy or diet only. Stable is defined as unchanged dose * Body mass index (BMI) between 20.0 and 35.0 kg/m2 (both inclusive) * HbA1c between 43 and 64 mmol/mol (6.0% - 8.0%) (both inclusive) * No use of platelet inhibiting therapy (e.g. aspirin, clopidogrel, ticagrelor, prasugrel) Exclusion Criteria: * All other forms of diabetes (type 1 diabetes, gestational diabetes) than type 2 diabetes mellitus * Treatment with any glucose lowering agent(s) other than metformin in a period of 60 days before screening. An exception is short-term treatment (≤ 7 days in total) with insulin due to intercurrent illness * Impaired hypoglycaemic awareness determined at the discretion of the investigator * Medical history of arrhythmia as atrial fibrillation, atrial flutter, atrioventricular dissociation disorders or ventricular arrhythmias * Previously known cardiovascular disease and / or past cardiovascular events, or past episodes of a congestive heart failure syndrome (NYHA II - NYHA IV) * Severe hypoglycaemic event requiring third party help in the last 6 months * Known allergy to human insulin or dextrose solution * Clinically significant abnormal haematology, biochemistry, lipids, hormones, coagulation or urinalysis * Uncontrolled hypertension defined as resting blood pressure at screening (after resting for 5 min, measured in sitting position) outside the range of 90-160 mmHg for systolic or 50-100 mmHg for diastolic * Chronic liver failure with severe liver dysfunction as assessed by the investigator * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) levels \> 3x upper Limit of normal (ULN) * estimated Glomerular Filtration Rate (eGFR) \<45 ml/min/1,73 m2 * Any musculoskeletal disorders holding back from stay in bed in a lying position during the time of the clamp experiments * Treatment with beta-blockers, antiarrhythmic agents or neuroleptic drugs * Active smoker or intake of illicit substances * Regular intake of nonsteroidal anti-inflammatory drugs (NSAIDs) * Any mental disorders or psychiatric conditions which may interfere with understanding or conduction of study related procedures * Females of child bearing potential without adequate contraceptive methods (i.e. sterilisation, intrauterine device, vasectomised partner; or medical history of hysterectomy)